Bluejay Diagnostics (NASDAQ:BJDX) versus Lucid Diagnostics (NASDAQ:LUCD) Critical Contrast

Lucid Diagnostics (NASDAQ:LUCD) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings for Lucid Diagnostics and Bluejay Diagnostics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1	0	4	0	2.60
Bluejay Diagnostics	1	0	0	0	1.00

Lucid Diagnostics currently has a consensus target price of $4.19, indicating a potential upside of 333.17%. Given Lucid Diagnostics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Lucid Diagnostics is more favorable than Bluejay Diagnostics.

Earnings and Valuation

This table compares Lucid Diagnostics and Bluejay Diagnostics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71 million	41.68	-$58.01 million	($0.47)	-2.06
Bluejay Diagnostics	N/A	N/A	-$6.85 million	($11.63)	-0.10

Bluejay Diagnostics has lower revenue, but higher earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Lucid Diagnostics has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, Bluejay Diagnostics has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500.

Insider and Institutional Ownership

74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are owned by institutional investors. 6.9% of Lucid Diagnostics shares are owned by insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Lucid Diagnostics and Bluejay Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-876.72%	N/A	-116.26%
Bluejay Diagnostics	N/A	-144.27%	-115.00%

Summary

Lucid Diagnostics beats Bluejay Diagnostics on 9 of the 13 factors compared between the two stocks.

About Lucid Diagnostics

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.